January 3, 2017
[Press release] MONCTON, NEW BRUNSWICK--(Marketwired - Dec 30, 2016) - Licensed medical marijuana producer Organigram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) ("Organigram" or the "Company") is voluntarily recalling certain lots of medical marijuana which were supplied between August and December 2016 due to the detection of amounts of an unapproved pesticide not registered for use on marijuana under the Pest Control Products Act.
Following discussions with Health Canada, this has been deemed a Type III recall, which is defined as "a situation in which the use of, or exposure to, dried marijuana, fresh marijuana or cannabis oil, marijuana plants or seeds is not likely to cause any adverse health consequences." The source of the substance is unknown as Organigram is a certified organic grower and does not use compounds of this nature in its production processes. The Company is cooperating with Health Canada officials to determine how the substance came into contact with the marijuana.
Organigram's client service department is directly notifying all clients affected by the recall. Any further action, if necessary, will be undertaken at the direction of Health Canada. Currently the number of lots affected is small, however, additional screening could result in additional lots being determined to be compromised. In the event that the number of contaminated lots significantly increases, the Company's operating revenue could be negatively affected.
Following discussions with Health Canada, this has been deemed a Type III recall, which is defined as "a situation in which the use of, or exposure to, dried marijuana, fresh marijuana or cannabis oil, marijuana plants or seeds is not likely to cause any adverse health consequences." The source of the substance is unknown as Organigram is a certified organic grower and does not use compounds of this nature in its production processes. The Company is cooperating with Health Canada officials to determine how the substance came into contact with the marijuana.
Organigram's client service department is directly notifying all clients affected by the recall. Any further action, if necessary, will be undertaken at the direction of Health Canada. Currently the number of lots affected is small, however, additional screening could result in additional lots being determined to be compromised. In the event that the number of contaminated lots significantly increases, the Company's operating revenue could be negatively affected.